Recurrent Malignant Glioma Clinical Trial
— OKN-007Official title:
Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
Verified date | March 2023 |
Source | Oblato, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot cohort of human recurrent malignant glioma patients. All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease with investigational agents or bevacizumab (Avastin). Patients with unequivocal recurrence (first or greater) established by MRI with and without contrast (e.g., Gd-DTPA (Gadolinium-diethylene triamine pentacetic acid) and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.
Status | Active, not recruiting |
Enrollment | 31 |
Est. completion date | October 2023 |
Est. primary completion date | January 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Confirmed histopathology of WHO grade III glioma or WHO grade IV GBM at primary diagnosis 2. Unequivocal radiographic evidence of tumor progression by MRI within 14 days prior to registration 3. Prior radiotherapy 4. Prior Temozolomide treatment 5. Last cytotoxic chemotherapy 28 or more days or biologic therapy treatment 14 or more days before study start (greater than or equal to 42 days if nitrosourea was administered) 6. Karnofsky performance status greater than or equal to 60% 7. Full recovery (< grade 1) from the toxic effects of any earlier intervention and a minimum of 28 days from the administration of any investigational agent 8. Adequate renal, liver and bone marrow function: - Leukocytes >3,000/mcL - Absolute neutrophil count >1,500/mcL - Platelets >100,000/mcL - Total bilirubin within normal limits - AST / ALT (SGPT) <2.5 x ULN - Creatinine within normal limits 9. Patients must be >_18 years of age Exclusion Criteria: 1. Second primary malignancy (except adequately treated basal cell carcinoma of the skin). Patients who had another malignancy in the past, but have been free of active disease for more than 2 years, are eligible 2. Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry 3. Serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study 4. Patients with moderate or severe renal impairment (calculated creatinine clearance of < 60 mL/min) 5. Patients with sodium, potassium, or creatinine serum electrolytes > grade 2. 6. Patients with PT/PTT above the upper limit of normal 7. Screening ECG abnormality documented by the investigator as medically significant |
Country | Name | City | State |
---|---|---|---|
United States | Oklahoma University | Oklahoma City | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Oblato, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Adverse events per patient | The primary objective is to determine MTD, tolerance, and safety of OKN-007 in patients with recurrent GBM and anaplastic glioma. | 24 months | |
Secondary | PK level in participants | To determine drug levels of OKN-007 in blood. | 24 months | |
Secondary | 6 month progression-free survival | To determine radiographic response rate and 6 month Progression-Free Survival (PFS) of patients treated with OKN-007. PFS is defined as the time from first drug treatment until objective tumor progression or death. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05045027 -
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
|
Early Phase 1 | |
Recruiting |
NCT04323046 -
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
|
Phase 1 | |
Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT03598244 -
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
|
Phase 1 | |
Recruiting |
NCT05278208 -
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03213665 -
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT04320888 -
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT05139056 -
Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
|
Phase 1 | |
Active, not recruiting |
NCT02208362 -
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
|
Phase 1 | |
Active, not recruiting |
NCT02192359 -
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
Unknown status |
NCT01144988 -
Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma
|
Phase 2 | |
Active, not recruiting |
NCT03210714 -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT04388475 -
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT04195555 -
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Recruiting |
NCT05540873 -
A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)
|
Phase 1 | |
Completed |
NCT01904123 -
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
|
Phase 1 | |
Active, not recruiting |
NCT02658279 -
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
|
N/A | |
Withdrawn |
NCT04521946 -
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
|
Phase 1 | |
Recruiting |
NCT04214392 -
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
|
Phase 1 | |
Recruiting |
NCT03896568 -
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
|
Phase 1 |